Vinay Prasad: ‘If something is highly promising, is it unethical to test that?’ in Washington Post (2016)

 

Personal Profile in the Portland Tribute (2016)

A remedy for a sick industry. Peter Korn. Mar 3, 2016

Prasad takes do no harm oath to heart. Peter Korn Mar 3, 2016

 

On Ending Medical Reversal:  When Evidence Says No, but Doctors Say Yes.  In Propublica and the Atlantic Monthly. February 2017.

Book Reviews for Ending Medical Reversal (Hopkins Press, 2015)

Best Health Care Books of 2015. Dr. Kenny Lin. Dec 7, 2015

Ending Medical Reversal is Revolutionary. Dr. Kenny Lin. Nov 11, 2015

Preventing Flip-Flops in Clinical Practice: Q&A.  MedPage Today. Nov 9, 2015

How Evidence Can Clean the House of Medicine.  MedPage Today. Nov 9, 2015

Ending Medical Reversal Laments Flip Flopping.  NY Times. Oct 30, 2015

A course in reversal.  The Lancet. Mar 26, 2016

***

Pharmaceutical advertisement for rare disease (JAMA 2017)

Big pharma's newest marketing tactic: infiltrating soap operas like General Hospital. VOX.

How a drug ad made its way into ‘General Hospital’. STAT.

The Tricky Ethics of Big Pharma Soft-Selling on Soap Operas. WIRED magazine

Doctors warn General Hospital cancer plot may be a sneaky pharmaceutical ad campaign. CBC radio

Is General Hospital Plot a Veiled Cancer Drug Ad?  Medscape.

Plot twist: Cheesy soap opera script is deceptive drug ad, doctors warn. Arstechnica.

 

Quoted regarding the fact 1/3 of FDA drugs later receive safety notifications

Nearly 1 In 3 FDA drug approvals followed by major safety actions. LA Daily News

 

Quoted regarding the cost and efficacy of PCSK-9 drug Repatha

This much-hyped cholesterol drug costs $14,100 a year. Doctors aren’t sure it’s worth it. VOX. 

 

Cost of cancer drugs (Nature reviews 2017)

Will the cost of cancer drugs break the economy? Modern Healthcare

 

Financial Conflicts Among Doctors on Twitter (Coverage of our JAMA IM 2017 paper)

What your doctor isn't telling you on Twitter.  Time Magazine.

OHSU study probes doctors' financial conflicts of interest on Twitter.  Portland Business News.

From Twitter To Treatment Guidelines, Industry Influence Permeates Medicine. NPR

Hidden Conflicts of Interest Found Throughout Medicine. MedPage Today

 

Quoted in Article about CAR-T cells

Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed? Xconomy

CAR-T therapy makes early inroads in treating brain cancer STAT

 

Patrick Soon Shiong's Moonshot has fallen short

He vowed to cure cancer. But this billionaire’s moonshot is falling far short of the hype. Stat. (2017)

 

Summary of multiple research papes

Dozens Of New Cancer Drugs Do Little To Improve Survival, Frustrating Patients. Liz Szabo. KHN. (2017)

This $94,000-a-year cancer drug caused rashes and rarely worked. Now Trump could make FDA approvals even easier. LA Times. Feb 2017

 

Judging Cancer Drugs by Clinical Not Statistical Benefit (2016)

Judging Cancer Drugs.  Medscape. Nov 4, 2016

 

Comments about FDA approval

Trump calls the FDA ‘slow and burdensome,’ but it’s faster than ever. Washington Post. 2017

FDA approval of $SRPT drug. Quartz.  Nov 1, 2016

 

Future jobs of FDA’s haematology-oncology reviewers

From FDA expert to biotech insider: The drug industry thrives on the revolving door. STAT Sept 27, 2016

A revolving door between FDA and the pharma industry raises questions about 'whether regulators indefatigably act in the public interest'  Business Insider Sept 27, 2016

When Drug Reviewers Leave The FDA, They Often Work For Pharma. Kaiser Health News. Sept 27. 2016.

Q&A: From FDA to Industry.  The Scientist. Sept 27, 2016

The FDA's revolving door raises ethical questions. Modern Healthcare. Sept 27, 2016

FDA's Cancer-Drug Reviewers Often Join Industry Later: Study.  Health Day. Sept 27. 2016

'Revolving Door' Between the FDA and Industry? Medscape. Sept 27, 2016

The FDA's drug reviewers keep leaving to work for big pharma, and it's a big problem.  Vox.  Sept 28, 2016

OHSU researcher shows revolving door between FDA, drug industry  Portland Business Journal.  Sept 28, 2016

Is the FDA Too Cozy With Drug Companies?  Time Magazine.  Sept 28, 2016

 

STAT Recommends as a Must Follow Twitter Account (2016)

‘Biocurious’ about biotech? Here are 10 must-follow Twitter accounts. Aug 22, 2016

 

Quoted

The rise of the unbranded pharmaceutical ad (CBS News)

 

Token Gesture when Disclosing Financial Conflict of Interest

Conflict of interest (JAMA Oncology 2016)

 

Screening for Lung Cancer (2016)

Family doctors don't always screen smokers for lung cancer. Fox News Health.

 

The FDA's Use of Untested Surrogate Endpoints (Mayo 2016)

Should Oncology Trials Rely Less on Overall Survival.  Cancer Therapy Advisor

Study raises questions FDA standards on new cancer drugs.  Milwaukee Journal Sentinel.

OHSU researcher: FDA's short-cut approval can lead to questionable cancer drugs. Portland Biz Journal.

We are spending 107 billion in cancer drugs, is it worth it?  Washington Post

 

On Medical Errors Now the Third Leading Cause of Death (2016)

Superficial coverage of medical errors could leave erroneous impression with readers. Health news reviews May 2016.

Don't believe what you read.  STAT. May 2016.

 

On Precision and Genomic Medicine (2016)

Genetics-based medicine a matter of debate Bend Bulletin.  May 2016.

 

On Paradigm-HF and Milt Packer (2016)

Unbelievable Folly of Clinical Trials.  Cardiobrief. March 2016

 

Cost of cancer drugs (2016)

This drug is defying a rare form of leukemia — and it keeps getting pricier. Carolyn Johnson. Washington Post. Mar 9, 2016

Cost of unused cancer drugs in the US.  The Lancet. March 10, 2016

 

Characteristics and Conflicts of Public Speakers at ODAC (JAMA IM 2016)

Cancer drug testimonals tinged with financial interest. MJS. Feb 1, 2016

FDA should make it easier to hear patients voices.  The Hill. Feb 25, 2016

Does Pharma Hijack Public Comment at FDA.  Medscape. Feb 2016.

 

Criticism of PARADIGM HF & Entresso Ad

Entresto Maker in Deep Water Over Terrifying TV Ad. Medscape. Feb 3, 2016.

 

On NEJM's Notorious "Data Parasite" Editorial 

NEJM Editor Backtracks on Data-Sharing 'Parasites' Editorial. Medscape Jan 26, 2016

New England Journal of Medicine increasingly targeted by critics. Boston Globe. Apr 5, 2016.

 

Why cancer screening has never been shown to “save lives” (BMJ 2016)

There is not enough proof screening works.  Time Magazine. Jan 7, 2016

Cancer screening benefits are overstated, experts claim. The Guardian. Jan 6, 2016

It is Misleading to Say Cancer Screening Saves Lives.  Newsweek. Jan 6, 2016

21 additional news outlets on Altmetric

 

Application of Medicare’s New Technology Add-on Payment Program for Blinatumomab (JAMA Oncology 2015)

Medicare's NTAP for Blinatumomab Should Be Questioned. Medscape. December 30, 2015

With Hands Tied, CMS' NTAP for Blinatumomab Is Ridden With Controversy. AJMC. Jan 5, 2016

 

Characteristics of Exceptional or Super Responders to Cancer Drugs

Super-Responder Buzzkill: Some Likely Have Indolent Cancers. MedPage Today. Nov 19, 2015

Dr. Vinay Prasad, an Assistant Professor of Medicine from the Oregon Health and Science University, in Portland, in his article appearing in the December 2015 issue of Mayo Clinic Proceedings, shows the contribution case reports can bring to precision medicine when the correct data surrounding them are collected and compared among super responders to cancer treatment.

 

Use of Superlatives in Cancer Research (JAMA Oncology 2015)

Cancer Reporting Needs Less Hype & More Hope. Real Clear Science. Jan 2016

3 Questions on... When Research Is Groundbreaking, Revolutionary, & Game-changing—and When It's Not. Dec 25, 2015

'Miracle cures'? Nope, OHSU says, it's just art of the sale. Portland Tribune. Nov 12, 2015

If a new cancer drug is hailed as a breakthrough odds are its not.  NPR Shorts.  Oct 29, 2015

Glowing terms often used for new cancer drugs in health news. Reuters. Oct 29, 2015

‘Revolutionary.’ ‘Game changer.’ ‘Miracle.’ How much are we hyping unproven cancer drugs? Washington Post. Oct. 29, 2015

Miracle or hype? News reports often inflate cancer drugs' success.  USA Today. Oct 29, 2015

What is the Most Hyped Drug in Cancer Care? Medscape. Oct. 29, 2015

Media Often Overplays Cancer Drug Research, Study Finds. US News and World Report.  Oct 29, 2015

That breakthrough game-changing miracle cancer drug is likely nothing of the sort. Incidental Economist. Oct 29, 2015.

In Drug Ca News.  Everything is Awesome! MedPage Today. Oct 29, 2015

OHSU: Some cancer drugs aren't the 'miracle' cures media makes them out to be. Portland Business Journal Oct 29, 2015

If A Cancer Drug Is Described As A Miracle, It Probably Isn't. Oregon Public Radio. Oct. 29, 2015.

 

Hard wired bias (Mayo Clinic Proceedings, 2015)

Top reads in slow medicine. MedPage Today. Nov 13, 2015

 

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals (JAMA IM 2015)

Few cancer drugs demonstrate OS benefit at time of FDA approval. HemOnc Today. Dec 30, 2015

Slippery slope: A targeted therapy that misses its mark. MedPage Today. Dec 12, 2015

FDA repeatedly approved Affinitor without proof it extended life. MJS. Dec 12, 2015

Surrogates for Survival or Other Endpoints. JAMA Oncology.  Nov 25, 2015.

Many cancer drugs may not help people live longer. NPR. Oct 23, 2015

Is 1 in 7 odds a breakthrough? Is it even promising? Health News Review.

Approved but not proven: What's up with FDA, cancer drugs? Medscape. Oct 22, 2015

Two-thirds of cancer drug approvals based on surrogate endpoints. APA. Oct 21, 2015

Early drug approvals can backfire.  Boston Globe.  Oct 20, 2015.

Study: Two-thirds of new cancer drugs don't extend life.  Milwaukee Journal Sentinel.  Oct 19, 2015

FDA Accelerated Cancer Drugs Don't Get Adequate Follow up.  MedPage Today. Oct 19, 2015

Researchers Question FDA's Use of Surrogate Endpoints for Cancer Drug Approvals. Oct 19, 2015

 

Cost of cancer drugs

Why do Specialty Drugs cost so much, and what can we do about it? Rhode Island Public Radio. Oct 15, 2015

 

Quoted in article about the NIH SPRINT trial

Raised Hype about Lower Blood Pressure.  Scientific America. Sept 21, 2015.

 

Panelist on the Diane Rehm's show regarding the controversy of treating DCIS

How Do We Treat Early Stage Breast Cancer? A New Study Revives The Debate.  NPR. Aug 24, 2015

 

Strength of Association Between Surrogate Endpoints and Survival (JAMA IM, 2015)

This bill promises to speed up drug approvals so much that it’s making people uncomfortable.  WSJ. July 10, 2015

 

Primary Care Physicians' Role in Counseling About Gun Safety (AAFP, 2015)

Talking With Patients about Guns? Show Some Respect

 

5 Years of Cancer Drug Approvals: Innovation, Efficacy, Cost (JAMA Onc, 2015)

Cancer Doctors Offer Way to Compare Medicines, Including by Cost. New York Times. June 22, 2015

Skyrocketing drug prices leave cures out of reach for some patients. USA Today.  June 15, 2015

Study Finds Oncology Drug Pricing Models 'Not Rational' - The ASCO Post, Apr. 9th 2015

US Cancer Drug Prices 'not rational' - PMLive, Apr. 8th 2015

No Real Rationale for Rising Cancer Drug Prices, JAMA Researchers Conclude - FiercePharma, Apr. 7th 2015

 

Modern Drug Development:  Which Patients Should Come First?  (JAMA, 2014)

Targeting Drug Development - The Incidental Economist, Nov 25th 2014

 

Mortality and Treatment Patterns Among Patients Hospitalized With Acute Cardiovascular Conditions During Dates of National Cardiology Meetings (JAMA IM, 2014)

The Doctor is Out, You May be in Luck - The New York Times, Dec 31st 2014

Some Heart Patients Do Better When the Cardiologist is Away - The LA Times, Dec 22nd 2014

Heart Care: Can Less Treatment Be Better? - USA Today, Dec 22nd 2014

 

The Withdrawal of Drugs for Commercial Reasons:  The Case of Tositumomab, An Incomplete Story (JAMA IM 2014)

Bexxar for Lymphoma: Gone but Not Forgotten - Medscape, DATE

Is a Drug Unsafe or Just Unprofitable? How a Lack of Data Clouds Regulatory Classifications - RAPS, Nov 14th 2014

 

Comparative Effectiveness Questions in Oncology (NEJM, 2014)

Cancer Drug Trials That Should, But Won't, Be Done - Medscape, DATE

Cancer Drugs: Too Expensive to Compare? - Modern Healthcare, Apr 17th 2014

High costs of cancer drugs preclude study for cheaper alternatives - Oncology Practice, Apr 16th 2014

 

Evidence Based De-implementation (Implementation Science, 2014)

Time to Consign What Doesn't Work to the Trash Bin - Prevention Action, Apr 16th 2014 - Prevention Action, Apr 16th 2014

 

Media Coverage of Medical Journals: Does the Media Select the best stories? (PLOS, 2014)

Media coverage of medical journals; do the best articles make the news? - F1000 Prime, Mar 25th 2014

US newspapers favor weaker studies, researchers say - British Medical Journal, Jan 24th 2014

Medical News: Evidence Not a Factor - Medpage Today, Jan 21st 2014

 

A Decade of Reversal:  An Analysis of 146 Contradicted Practices (Mayo, 2013)

Dr. Vinay Prasad, Chief Fellow of Medical Oncology for the National Cancer Institute and the National Institutes of Health in Bethesda, MD, discusses his article appearing in the August 2013 issue of Mayo Clinic Proceedings, where he answers the questions "What are we getting right and what are we getting wrong?'

Medical Procedures may be Useless or Worse - The New York Times, July 26th 2013

Pressed To Demonstrate Utility, Digital Health Struggles -- Just Like Traditional Medicine - Forbes, Jan 7th 2014

Changes in Modern Medicine: What Can We Expect? - The Huffington Post, Jan 30th 2014

Keeping patients front and centre in the era of negative results - The Lancet Oncology, Sept, 2013

Studies often overturn accepted medical practice, analysis finds - British Medical Journal, July 26th 2013

Newly established medical practices often prove to be ineffective, study finds - The Minneapolis Post, July 31st 2013

More Medical Procedures that Don't Work - Men's Journal, Oct 2013

Reversal of established medical practice - Australian Broadcasting Company, July 29th 2013

 

The Inferior Vena Cava Filter (JAMA IM, 2013)

Filters often used to stop clots without evidence - Reuters, Mar 19th 2013

Vena Cava Filters: Little Evidence and Wide Variation in Use - Forbes, Mar 18th 2013

No Standard for Vena Cava Filter Use - Medpage Today, Mar 18th 2013

 

Chest Pain in the Emergency Room (Archives Internal Medicine, 2012)

Chest Pain in the Emergency Room - Heartwire, Date

 

The Diagnosis and Treatment of Pulmonary Embolism (Archives Internal Medicine, 2012)

Richard Lehman's Journal Review - British Medical Journal, July 9th 2012

http://www.scientificamerican.com/article/statins-should-healthy-adults-over-50-take-them/

 

Cardiovascular Primary Prevention (Archives Internal Medicine, 2012)

The Statis on Statins: Should Healthy Adults Over 50 Take Them? - Scientific American, May 21st 2012

 

Reversal of Contradicted Medical Practices (JAMA, 2012)

Bias and error are rampant in medical literature - KevinMD, Mar 18th 2012

 

The Frequency of Medical Reversal (Archives Internal Medicine, 2011)

So how often does medical consensus turn out to be wrong? - Retraction Watch, July 11th 2011

New Studies Often Reverse Existing Practices - Medpage Today, July 11th 2011

Health 'truths' overturned: New medical information might change some long-held beliefs (print only) - Consumer Reports on Health, 2011